ipxl result wait merger close
messag report result lower expect revenu in-
line adjust ep report stand-alone guidanc quarter plan
provid combin amneal-impax compani guidanc merger close expect
merger gain scale scope complex manufactur
importantli pipelin await clariti time pipelin merger
close maintain neutral rate
result ipxl report revenu our/street estim
gener revenu declin y/i q/q
quarterli declin attribut lower epinephrin season diclofenac gel
sale manag indic diclofenac gel tough q/q comparison strong
custom mix specialti sale grew y/i larg due strength
rytari zomig franchis manag optimist maintain rytari
strength adj ep in-lin street estim
amneal ipxl announc amneal plan report result manag
indic amneal strong year behind strong commerci perform
anda approv new product launch file anda note
symphoni health prescript data also indic y/i growth dollar basi
amneal amneal today announc launch gtamiflu oral suspens
gtamiflu gener product launch amneal gconcerta
gaccutan gentocort gnameda xr respect biosimilar program amneal
file bla biosimilar neupogen fda accept applic
septemb plan file bla biosimilar neulasta
pipelin manag indic ipxl date certain launch
beyond launch solodyn author gener ipxl still await fda approv
gwelchol hope first wave approv launch quantiti
readi follow final fda approv gestrac receiv januari ipxl
partner expect launch report sale
product believ ipxl/prgo third gener entrant behind obtain
approv teva launch author gener
regard specialti pipelin ipxl announc plan begin phase studi
evalu parkinson diseas follow merger close ipxl-amn
provid addit commentari combin compani pipelin guidanc
close expect
model chang revenu estim stand-alone ipxl move vs
prior declin reflect quarterli run-rat decreas
gener segment adj ep howev increas vs prior
acceler cost improv program ipxl indic achiev
run-rat save maintain neutral rate
page analyst certif import disclosur
valu use rel valuat ev/ebitda methodolog trade
in-lin gener group averag ev/ebitda believ appropri
given impax risk/benefit profil pend merger maintain neutral rate
risk includ longer expect fda approv timelin higher
expect cost failur success introduc new product market failur
penetr highli generic market obtain approv merger amneal
may delay complet fda may request remov gener opana er
clinic develop risk inabl compani gain approv fda
limit intellectu properti ip protect control trade secret
technolog innov abil competitor independ develop similar better
proprietari inform techniqu disclos publicli success compet
therapi product becom avail medicar medicaid insur
increas effort manag drug spend econom weak impact unemploy
commerci insur coverag util forecast error determin impax
market opportun risk includ compani may requir substanti addit
fund may financ futur cash need primarili public privat offer debt
financ strateg collabor may dilut stockhold compani
convers impax-amn merger could close sooner anticip achiev
synergi faster expect compani respect pipelin could see
acceler fda approv timelin key product like copaxon xyrem
approv pend anda result potenti upsid estim
page analyst certif import disclosur
servic
total servic
revenu
revenu
litigation-rel
acquisition-rel charg
purchas in-process
depreci amort
sale/merg expens
interest dividend incom
reserv ture receiv
sale assets/intang
realiz gain loss invest
unreal gain loss invest
discountinu op net tax
total servic
compani report guggenheim secur llc estim
page analyst certif import disclosur
